Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data

Published: Wednesday, April 04, 2012
Last Updated: Tuesday, April 03, 2012
Bookmark and Share
Phase 1/2 MDS and AML data was presented at AACR 2012 annual meeting in Chicago.

Astex Pharmaceuticals, Inc. has announced that interim Phase 1/2 clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good tolerability, and preliminary promising complete responses in heavily pretreated acute myelogenous leukemia (AML) patients enrolled in the Phase 1 segment of the trial.

The data was presented at an oral session at the American Association for Cancer Research (AACR) 2012 Annual Meeting in Chicago, IL and was featured in a joint AACR-Stand Up To Cancer (SU2C) media forum.

SU2C has provided funding for the Epigenetics Dream Team that is collaborating on the scientific evaluation of SGI-110.

The randomized Phase 1/2 first-in-human dose escalation study enrolled 66 patients with previously treated intermediate or high-risk myelodysplastic syndromes (MDS) or AML as of March 28, 2012.

Of seven evaluable refractory AML patients who had adequate hypomethylation with no prior resistance to hypomethylating agents (HMAs), two showed complete response, and one showed partial response.

Additionally, the pharmacokinetic (PK) data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure and longer half-life than decitabine intravenous (IV) infusion.

The pharmacodynamic (PD) data shows potent dose-dependent hypomethylation induction in the daily regimen.

“This interim SGI-110 data is very encouraging for refractory AML patients,” said Jean-Pierre Issa, MD, professor of medicine and director of the Fels Institute for Cancer Research and Molecular Biology at Temple University.

Issa continued, “With the optimal biologically effective dose reached, this provides a firm basis to begin the dose expansion segment of the trial for treatment of elderly AML and previously untreated MDS.”

“This is a great example of collaboration between SU2C and industry,” said Stephen B. Baylin, MD, professor of oncology and medicine, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; co-leader of the Epigenetics Dream Team of SU2C.

Baylin continued, “The trial used a biologically driven design where dose escalation was based on biological efficacy of the drug and not just toxicities as is often the case with cancer drugs. Achieving clinical efficacy at the biologically effective doses is a validation of this innovative design."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Astex Pharmaceuticals Reports 2012 First Quarter Financial Results
Reports first quarter net income of $4.2 million.
Tuesday, May 01, 2012
Scientific News
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
The Fight Against Fungal Infections
A pioneering university research team has recently employed such a system within their laboratory to obtain a greater understanding of the dynamics and progression of C. albicans in vivo using a mouse model.
Fly Study into Therapies for HVP-Induced Cancer
Fruit flies may help scientists understand the mechanism by which HPV can cause cancer as well as identify potential drug treatments.
Exploring Ebola-Malaria Link
Data shows people infected with Ebola were more likely to survive if co-infected with malarial parasite.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
Characterizing the Mouse Gut Microbiome
Study establishes the first public collection of bacteria from the intestine of mice.
Common Drug Shows Potential as Alzheimer's Cure
A research project has shown that an experimental model of Alzheimer’s disease can be successfully treated with a commonly used anti-inflammatory drug.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Magnetic Drug Delivery in the Body
Imagine a device that could transport drugs to any diseased site in the body with the help of a small magnet.
The Power of Model Systems
New insights into the influence of host on the gut microbiome are revealed with in situ light sheet fluorescence microscopy and stochastic mathematical modelling.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!